High Commissioner Calls for Indian Companies to Expand Manufacturing in Sri Lanka
During the Pharma MakTech Expo and Labnext 2026 in New Delhi, High Commissioner Maheshini Kolon appealed to Indian pharmaceutical players to look beyond domestic borders and set up production units in Sri Lanka.
She stressed that Sri Lanka's current dependence on imported medicines leaves a clear demand gap that Indian firms can fill through active pharmaceutical ingredients, medical device assembly, and advanced diagnostic tools.
The Sri Lankan authorities have prioritized the pharma sector, granting long‑term tax holidays and fast‑track licensing through the National Medicines Regulatory Authority. Kolon highlighted the Hambantota Special Pharmaceutical Manufacturing Zone as an ideal location, offering ready infrastructure and incentives.
The existing India‑Sri Lanka Free Trade Agreement already provides duty‑free entry for more than 50 pharma and medical device categories into the Indian market, enhancing the commercial appeal for investors.
Kolon concluded by encouraging Indian businesses to attend the Sri Lanka Expo 2027, a major trade and investment showcase scheduled for mid‑January 2027 in Colombo, where they can explore partnership opportunities and discuss technology transfer, skill development, and research collaborations.